192 related articles for article (PubMed ID: 32653374)
1. Kinetic and thermodynamic insights into interaction of erlotinib with epidermal growth factor receptor: Surface plasmon resonance and molecular docking approaches.
Mohammadzadeh-Asl S; Aghanejad A; Yekta R; de la Guardia M; Ezzati Nazhad Dolatabadi J; Keshtkar A
Int J Biol Macromol; 2020 Nov; 163():954-958. PubMed ID: 32653374
[TBL] [Abstract][Full Text] [Related]
2. Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies.
Kiriwan D; Seetaha S; Jiwacharoenchai N; Tabtimmai L; Sousa SF; Songtawee N; Choowongkomon K
Chem Biol Drug Des; 2022 Mar; 99(3):456-469. PubMed ID: 34923743
[TBL] [Abstract][Full Text] [Related]
3. Bovine serum albumin binding study to erlotinib using surface plasmon resonance and molecular docking methods.
Taghipour P; Zakariazadeh M; Sharifi M; Ezzati Nazhad Dolatabadi J; Barzegar A
J Photochem Photobiol B; 2018 Jun; 183():11-15. PubMed ID: 29679689
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
Yang X; Hou Z; Wang D; Mou Y; Guo C
Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
[TBL] [Abstract][Full Text] [Related]
5. Computational identification of new TKI as potential noncovalent reversible EGFR
Abdelmalek D; Smaoui F; Frikha F; Ben Marzoug R; Msalbi D; Souissi A; Aifa MS
J Biomol Struct Dyn; 2024 Jun; 42(9):4870-4887. PubMed ID: 37349947
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
Panicker PS; Melge AR; Biswas L; Keechilat P; Mohan CG
Chem Biol Drug Des; 2017 Oct; 90(4):629-636. PubMed ID: 28303669
[TBL] [Abstract][Full Text] [Related]
7. Imidazole[1,5-a]pyridine derivatives as EGFR tyrosine kinase inhibitors unraveled by umbrella sampling and steered molecular dynamics simulations.
Truong DT; Ho K; Nhi HTY; Nguyen VH; Dang TT; Nguyen MT
Sci Rep; 2024 May; 14(1):12218. PubMed ID: 38806555
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the binding characteristics between ligands and epidermal growth factor receptor by cell membrane chromatography.
Yang L; Zhu M; Kang Y; Yang T; Ma W
J Mol Recognit; 2018 Jun; 31(6):e2701. PubMed ID: 29363191
[TBL] [Abstract][Full Text] [Related]
9. Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents.
Minnelli C; Laudadio E; Mobbili G; Galeazzi R
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32138321
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.
Kim DM; Kim MJ; Moon JH; Lee EY; Hong JK; Lee S; Koh DI; Ryu YS; Kim SM; Jung SA; Shin JS; Kim J; Park YS; Hong SW; Lee SH; Jung J; Park SS; Kim DY; Kim EH; Jeong HR; Gong JH; Kim J; Chan Kim S; Yu HN; Ki SY; Kim TW; Jin DH
Biochem Biophys Res Commun; 2020 Jun; 527(1):305-310. PubMed ID: 32446385
[TBL] [Abstract][Full Text] [Related]
11. Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies.
Aiebchun T; Mahalapbutr P; Auepattanapong A; Khaikate O; Seetaha S; Tabtimmai L; Kuhakarn C; Choowongkomon K; Rungrotmongkol T
Molecules; 2021 Apr; 26(8):. PubMed ID: 33921332
[TBL] [Abstract][Full Text] [Related]
12. Potent and selective EGFR inhibitors based on 5-aryl-7H-pyrrolopyrimidin-4-amines.
Reiersølmoen AC; Aarhus TI; Eckelt S; Nørsett KG; Sundby E; Hoff BH
Bioorg Chem; 2019 Jul; 88():102918. PubMed ID: 30999245
[TBL] [Abstract][Full Text] [Related]
13. In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD.
Mir SA; Dash GC; Meher RK; Mohanta PP; Chopdar KS; Mohapatra PK; Baitharu I; Behera AK; Raval MK; Nayak B
Appl Biochem Biotechnol; 2022 Oct; 194(10):4292-4318. PubMed ID: 35366187
[TBL] [Abstract][Full Text] [Related]
14. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
Sangande F; Julianti E; Tjahjono DH
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
[TBL] [Abstract][Full Text] [Related]
15. Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors.
Gómez-Ganau S; Castillo J; Cervantes A; de Julián-Ortiz JV; Gozalbes R
Curr Top Med Chem; 2020; 20(18):1628-1639. PubMed ID: 32493189
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
17. In Silico Identification of Novel Erlotinib Analogues Against Epidermal Growth Factor Receptor.
Sheikh IA; Hassan HM
Anticancer Res; 2016 Nov; 36(11):6125-6132. PubMed ID: 27793941
[TBL] [Abstract][Full Text] [Related]
18. Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib.
Mathew MP; Tan E; Saeui CT; Bovonratwet P; Liu L; Bhattacharya R; Yarema KJ
Bioorg Med Chem Lett; 2015 Mar; 25(6):1223-7. PubMed ID: 25690786
[TBL] [Abstract][Full Text] [Related]
19. Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy.
Li YL; Hu X; Li QY; Wang F; Zhang B; Ding K; Tan BQ; Lin NM; Zhang C
Mol Med Rep; 2018 Oct; 18(4):3882-3890. PubMed ID: 30106133
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, Molecular Docking, and Biological Evaluation of Isatin-Based Fused Heterocycles As Epidermal Growth Factor Receptor Inhibitors.
Kumar A; Kumar B; Bhatia R
Assay Drug Dev Technol; 2023 Jul; 21(5):222-233. PubMed ID: 37439798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
